Premium
Genistein treatment protects mice from ionizing radiation injury
Author(s) -
Landauer Michael R.,
Srinivasan Venkataraman,
Seed Thomas M.
Publication year - 2003
Publication title -
journal of applied toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.784
H-Index - 87
eISSN - 1099-1263
pISSN - 0260-437X
DOI - 10.1002/jat.904
Subject(s) - genistein , saline , toxicity , acute toxicity , pharmacology , ionizing radiation , histopathology , medicine , chemistry , irradiation , pathology , physics , nuclear physics
The radioprotective and behavioral effects of an acute administration of the isoavone genistein (4′,5,7‐trihydroxyavone) were investigated in adult CD2F1 male mice. Mice were administered a single subcutaneous (s.c.) dose of genistein either 24 h or 1 h before a lethal dose of gamma radiation (9.5‐Gy of cobalt‐60 at 0.6 Gy min −1 ). Mice received saline, PEG‐400 vehicle or genistein at 3.125, 6.25, 12.5, 25, 50, 100, 200, or 400 mg kg −1 body weight. For mice treated 24 h before irradiation there was a signicant increase in 30‐day survival for animals receiving genistein doses of 25 to 400 mg kg −1 ( p < 0.001). In contrast, the 30‐day survival rates of mice treated with genistein 1 h before irradiation were not signicantly different from those of the vehicle control group. Additionally, the acute toxicity of genistein was evaluated in non‐irradiated male mice administered a single s.c. injection of saline, vehicle, or genistein at 100, 200 or 400 mg kg −1 . At these genistein doses there were no adverse effects, compared with controls, on locomotor activity, grip strength, motor coordination, body weight, testes weight, or histopathology. These results demonstrate that a single s.c. administration of the avonoid genistein at non‐toxic doses provides protection against acute radiation injury. Published in 2003 by John Wiley & Sons, Ltd.